Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 2
1997 1
1998 1
2008 1
2011 2
2012 1
2013 2
2014 2
2015 1
2018 1
2019 3
2020 2
2021 2
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D; Huntington Study Group KINECT-HD Collaborators. Furr Stimming E, et al. Lancet Neurol. 2023 Jun;22(6):494-504. doi: 10.1016/S1474-4422(23)00127-8. Lancet Neurol. 2023. PMID: 37210099 Clinical Trial.
The study included adults with genetically confirmed Huntington's disease and chorea (Unified Huntington's Disease Rating Scale [UHDRS] Total Maximal Chorea [TMC] score of 8 or higher) who were randomly assigned (1:1) via an interactive web response system (with no stratification …
The study included adults with genetically confirmed Huntington's disease and chorea (Unified Huntington's Disease Rating Scale [UHDRS] Tota …
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J; De-ESCALaTE HPV Trial Group. Mehanna H, et al. Lancet. 2019 Jan 5;393(10166):51-60. doi: 10.1016/S0140-6736(18)32752-1. Epub 2018 Nov 15. Lancet. 2019. PMID: 30449623 Free PMC article. Clinical Trial.
Overall (acute and late) severe (grade 3-5) toxicity did not differ significantly between treatment groups at 24 months (mean number of events per patient 4.8 [95% CI 4.2-5.4] with cisplatin vs 4.8 [4.2-5.4] with cetuximab; p=0.98). At 24 months, overall all-grade toxicity …
Overall (acute and late) severe (grade 3-5) toxicity did not differ significantly between treatment groups at 24 months (mean number …
Oral Human Papillomavirus Prevalence and Genotyping Among a Healthy Adult Population in the US.
Giuliano AR, Felsher M, Waterboer T, Mirghani H, Mehanna H, Roberts C, Chen YT, Lynam M, Pedrós M, Sanchez E, Sirak B, Surati S, Alemany L, Morais E, Pavón MA. Giuliano AR, et al. JAMA Otolaryngol Head Neck Surg. 2023 Sep 1;149(9):783-795. doi: 10.1001/jamaoto.2023.1573. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 37535349 Free PMC article.
MAIN OUTCOME: Oral HPV prevalence. RESULTS: Of the 3196 participants enrolled, mean (SD) age was 39.6 (12.1) years, and 55.5% were women. Oral HPV prevalence was 6.6% (95% CI, 5.7%-7.4%) for any HPV genotype, and 2.0% (95% CI, 1.5%-2.5%), 0.7% (95% CI, 0.4%-1.0%), and 1.5% …
MAIN OUTCOME: Oral HPV prevalence. RESULTS: Of the 3196 participants enrolled, mean (SD) age was 39.6 (12.1) years, and 55.5% were wo …
Functional movement disorder gender, age and phenotype study: a systematic review and individual patient meta-analysis of 4905 cases.
Lidstone SC, Costa-Parke M, Robinson EJ, Ercoli T, Stone J; FMD GAP Study Group. Lidstone SC, et al. J Neurol Neurosurg Psychiatry. 2022 Jun;93(6):609-616. doi: 10.1136/jnnp-2021-328462. Epub 2022 Feb 25. J Neurol Neurosurg Psychiatry. 2022. PMID: 35217516 Free article.
A total of 4905 individual cases were analysed (72.6% woman). The mean age at onset was 39.6 years (SD 16.1). Women had a significantly earlier age of onset than men (39.1 years vs 41.0 years). Mixed FMD (23.1%), tremor (21.6%) and weakness (18.1%) were the most common phe …
A total of 4905 individual cases were analysed (72.6% woman). The mean age at onset was 39.6 years (SD 16.1). Women had a significant …
Open conservation partial laryngectomy for laryngeal cancer: a systematic review of English language literature.
Thomas L, Drinnan M, Natesh B, Mehanna H, Jones T, Paleri V. Thomas L, et al. Cancer Treat Rev. 2012 May;38(3):203-11. doi: 10.1016/j.ctrv.2011.05.010. Epub 2011 Jul 20. Cancer Treat Rev. 2012. PMID: 21764220 Review.
The pooled local control rate at 24 months from 5061 patients was 89.8% (95% CI 88.3-91.2), pooled overall survival was 79.7% (n = 3967; 95% CI 76.5-782.8) and pooled mean disease free survival was 84.8% (n = 2344; 95% CI 80.6-88.7). The pooled mean operative mortal …
The pooled local control rate at 24 months from 5061 patients was 89.8% (95% CI 88.3-91.2), pooled overall survival was 79.7% (n = 3967; 95% …
Oncologic outcomes of transoral laser microsurgery for radiorecurrent laryngeal carcinoma: a systematic review and meta-analysis of English-language literature.
Ramakrishnan Y, Drinnan M, Kwong FN, Grant DG, Mehanna H, Jones T, Paleri V. Ramakrishnan Y, et al. Head Neck. 2014 Feb;36(2):280-5. doi: 10.1002/hed.23291. Epub 2013 Jun 14. Head Neck. 2014. PMID: 23766141 Review.
Pooled estimates of local control at 24 months, disease-free survival (DFS), and overall survival (OS) rates were calculated. RESULTS: The pooled mean estimates were: local control rate at 24 months after first TLM (n = 249), 56.9% (95% confidence interval [CI], 47.4-66.1) …
Pooled estimates of local control at 24 months, disease-free survival (DFS), and overall survival (OS) rates were calculated. RESULTS: The p …
In-vitro evaluation of the shear bond strength and fluoride release of a new bioactive dental composite material.
Rifai H, Qasim S, Mahdi S, Lambert MJ, Zarazir R, Amenta F, Naim S, Mehanna C. Rifai H, et al. J Clin Exp Dent. 2022 Jan 1;14(1):e55-e63. doi: 10.4317/jced.58966. eCollection 2022 Jan. J Clin Exp Dent. 2022. PMID: 35070125 Free PMC article.
Kolmogorov-Smirnov and Levene tests were used to evaluate the distribution of the variable and the equality of variances respectively and a Student's T- test was applied to compare the mean strength between the groups. ...It was followed by univariate analyses and B …
Kolmogorov-Smirnov and Levene tests were used to evaluate the distribution of the variable and the equality of variances respectively and a …
Oncologic outcomes of open conservation laryngectomy for radiorecurrent laryngeal carcinoma: a systematic review and meta-analysis of English-language literature.
Paleri V, Thomas L, Basavaiah N, Drinnan M, Mehanna H, Jones T. Paleri V, et al. Cancer. 2011 Jun 15;117(12):2668-76. doi: 10.1002/cncr.25831. Epub 2011 Feb 1. Cancer. 2011. PMID: 21287526 Free article. Review.
Decannulation of tracheostomy occurred in 95.1% (95% CI, 92.6%-97.2%) of the patients who were analyzed (n = 315), whereas the pooled mean larynx preservation rate was 83.9% (95% CI, 80.7%-87%; n = 502) CONCLUSIONS: The current results indicated that open partial laryngect …
Decannulation of tracheostomy occurred in 95.1% (95% CI, 92.6%-97.2%) of the patients who were analyzed (n = 315), whereas the pooled mea …
Characterizing the epithelial-mesenchymal transition status of circulating tumor cells in head and neck squamous cell carcinoma.
Payne K, Brooks J, Batis N, Taylor G, Nankivell P, Mehanna H. Payne K, et al. Head Neck. 2022 Nov;44(11):2545-2554. doi: 10.1002/hed.27167. Epub 2022 Aug 5. Head Neck. 2022. PMID: 35932094 Free PMC article.
METHOD: Blood samples from 20 treatment naive HNSCC patients underwent Parsortix enrichment and flow cytometry analysis to quantify CTCs and identify epithelial or EMT subgroups-correlated to clinical outcomes and EMT gene-expression in tumor tissue. RESULTS: CTCs were detected i …
METHOD: Blood samples from 20 treatment naive HNSCC patients underwent Parsortix enrichment and flow cytometry analysis to quantify CTCs and …
Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up.
Mehanna H, Al-Maqbili T, Carter B, Martin E, Campain N, Watkinson J, McCabe C, Boelaert K, Franklyn JA. Mehanna H, et al. J Clin Endocrinol Metab. 2014 Aug;99(8):2834-43. doi: 10.1210/jc.2013-2118. Epub 2014 May 14. J Clin Endocrinol Metab. 2014. PMID: 24828487 Review.
RESULTS: Of 1102 abstracts identified, 262 studies were reviewed and 17 studies included, comprising 3523 subjects, with mean follow-up of 70 months and total follow-up of 21 329 person-years. This included 854 subjects with incidental PTMC (follow-up, 4800 person-years; …
RESULTS: Of 1102 abstracts identified, 262 studies were reviewed and 17 studies included, comprising 3523 subjects, with mean follow- …
22 results